These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 7516372

  • 1. [Finasteride in the treatment of benign prostatic hypertrophy].
    Ekman P.
    J Urol (Paris); 1993; 99(6):299-302. PubMed ID: 7516372
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review.
    Ekman P.
    Arch Esp Urol; 1994 Nov; 47(9):883-7; discussion 887-8. PubMed ID: 7530944
    [Abstract] [Full Text] [Related]

  • 3. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P.
    J Urol (Paris); 1995 Nov; 101(1):22-5. PubMed ID: 7545721
    [Abstract] [Full Text] [Related]

  • 4. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P, Andersen JT, Wolf H.
    Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [New prospective therapy for benign prostatic hyperplasia with finasteride].
    Miano L, Manieri C, Paradiso Galatioto G, Vicentini C.
    Riv Eur Sci Med Farmacol; 1993 Mar; 15(2):111-9. PubMed ID: 7513437
    [Abstract] [Full Text] [Related]

  • 7. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ, Beisland HO, Andersen JT, Wolf H, Ekman P, Johansson JE, Kontturi M, Lehtonen T.
    Tidsskr Nor Laegeforen; 1996 Nov 10; 116(27):3226-30. PubMed ID: 9011975
    [Abstract] [Full Text] [Related]

  • 8. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
    Andersen JT, Wolf H, Ekman P, Beisland HO, Johansson JE, Kontturi M, Lehtonen T, Tveter K.
    Ugeskr Laeger; 1996 Sep 02; 158(36):5030-5. PubMed ID: 8928243
    [Abstract] [Full Text] [Related]

  • 9. Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study.
    Lukkarinen O, Lehtonen T, Talja M, Lundstedt S, Tiitinen J, Taari K.
    Ann Chir Gynaecol; 1999 Sep 02; 88(4):299-303. PubMed ID: 10661828
    [Abstract] [Full Text] [Related]

  • 10. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996 Sep 02; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 11. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA.
    Arch Esp Urol; 1999 Apr 02; 52(3):201-8. PubMed ID: 10371735
    [Abstract] [Full Text] [Related]

  • 12. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA.
    East Afr Med J; 1998 May 02; 75(5):260-3. PubMed ID: 9746993
    [Abstract] [Full Text] [Related]

  • 13. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O, Oishi K, Okada Y, Mizutani Y, Itokawa Y, Tomoyoshi T, Okada K, Komatz Y, Matsuda T, Takeuchi H.
    Hinyokika Kiyo; 1996 Apr 02; 42(4):323-31. PubMed ID: 8693970
    [Abstract] [Full Text] [Related]

  • 14. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 02; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up].
    Martínez Sarmiento M, Cuñat Albert E, López Alcina E, Pontones Moreno JL, Sanz Chinesta S, Jiménez Cruz JF.
    Actas Urol Esp; 1997 Feb 02; 21(2):105-10. PubMed ID: 9214205
    [Abstract] [Full Text] [Related]

  • 16. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan 02; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 17. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
    Shibata Y, Fukabori Y, Ito K, Suzuki K, Yamanaka H.
    J Urol; 2001 Jan 02; 165(1):289-93. PubMed ID: 11125427
    [Abstract] [Full Text] [Related]

  • 18. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H, Chen J, Braf Z.
    Harefuah; 1993 Dec 15; 125(12):453-6, 496. PubMed ID: 7509305
    [Abstract] [Full Text] [Related]

  • 19. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.
    Matsumoto AM, Tenover L, McClung M, Mobley D, Geller J, Sullivan M, Grayhack J, Wessells H, Kadmon D, Flanagan M, Zhang GK, Schmidt J, Taylor AM, Lee M, Waldstreicher J, Pless Study Group.
    J Urol; 2002 May 15; 167(5):2105-8. PubMed ID: 11956450
    [Abstract] [Full Text] [Related]

  • 20. Clinical and biological characteristics of familial benign prostatic hyperplasia.
    Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, Stoner E, Walsh PC.
    J Urol; 1997 Mar 15; 157(3):876-9. PubMed ID: 9072590
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.